Elsevier Acquires Aureus Sciences, Provider of Databases and Information Tools for Pharmaceutical and Biotech Companies
AMSTERDAM, January 8, 2013 /PRNewswire/ –
Elsevier to expand its suite of solutions to cover the entire drug discovery
and development value chain by launching new life sciences solutions
Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, announced today the acquisition of Aureus
Sciences [http://www.aureus-sciences.com/aureus/web/guest ], a Paris, France based
privately held company that provides databases and information tools to pharmaceutical and
Formed in 2002, Aureus Sciences gathers unique and high quality quantitative
biological activity data for major therapeutic drug targets. This content enables
researchers to identify the most promising compounds, repurpose existing compounds and
identify targets with which the new compounds might interact.
“The acquisition of Aureus Sciences provides us with tremendous opportunities to
generate more value for our customers,” said Mark van Mierle, Managing Director Elsevier
Pharmaceutical and Biotech Group. “With the combination of Aureus content assets and the
content already available by Elsevier, we can create a valuable solution for those in need
of improving speed and accuracy of lead-finding, decision-making and other key processes.”
The acquisition enables the combination of high quality and deeply extracted content
from both companies to launch new solutions for our Pharmaceutical and Biotech customers.
The first evidence of this will be seen early this year with the release of a new
medicinal chemistry solution.
“The integration of Aureus into Elsevier, and the consolidation of best in class
content, will complement Elsevier’s leadership in biomedical disciplines and strengthen
our ability to offer new innovative databases to researchers in medicinal chemistry and
pharmacology,” said Jason Theodosiou, CEO of Aureus Sciences. “We will see many positive
synergies resulting from this combination.”
The acquisition is effective immediately and financial terms of the transaction are
not being disclosed.
About Aureus Sciences
Headquartered in Paris, Aureus Sciences provides scientific databases and software
applications for researchers involved in the drug discovery and development process.
Furthermore, the company focuses on providing solutions to the needs of pharmaceutical and
biotech companies to leverage information and knowledge as a decision making tool and to
increase the speed and efficiency of their drug discovery and development process. Over
the course of 10 years and with a significant investment, the Company has developed a
unique Knowledge Production Platform which analyzes, indexes, and organizes critical
chemical and bioactivity information into databases.
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[http://www.clinicalkey.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact Christopher Capot Director, Corporate Relations Elsevier +1-212-633-3164 firstname.lastname@example.org